StockData
Eton Pharmaceuticals, Inc. logo

Eton Pharmaceuticals, Inc. (ETON) stock

ETONNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30524% above fair value
$63.65−0.23 (-0.36%)

Close on Nov 17, 2026Market cap $1.82BP/E 163.2Yield –

Eton Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Eton Pharmaceuticals's price to sales ratio was 18.3× on Nov 11, 2026, against 6.2× a year earlier. Over the last 5 years it ranged from 2.5× to 18.3×, with a median of 5.4×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202618.3×+11.9
2025Dec 31, 20256.4×−3.5
2024Dec 31, 20249.9×+6.5
2023Dec 29, 20233.4×−0.4
2022Dec 30, 20223.8×−2.9
2021Dec 31, 20216.7×−402.5
2020Dec 31, 2020409.2×–

More Eton Pharmaceuticals figures

See a number that looks wrong?